| HS Code | 652368 |
| Product Name | Swine Erysipelas Vaccine, Live Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions |
| Product Type | Live bacterial vaccine / veterinary biological API |
| Active Ingredient | Live attenuated Erysipelothrix rhusiopathiae |
| Target Species | Swine / pigs |
| Indication | Active immunization against swine erysipelas caused by Erysipelothrix rhusiopathiae |
| Vaccine Type | Live vaccine |
| Veterinary Grade | Veterinary-grade active pharmaceutical ingredient |
| Suitable Dosage Forms | Tablets, injections, capsules, powders, granules, premix, and solutions |
| Route Of Administration | Oral or parenteral depending on final formulated dosage form |
| Storage Conditions | Store at 2–8°C, protected from light and moisture |
| Shelf Life | Typically 18–24 months from manufacture date under recommended storage |
| Withdrawal Period | Zero days as per approved veterinary use |
| Adjuvants Excipients | May contain approved stabilizers / preservatives to maintain live organism potency |
| Immunity Mechanism | Stimulates active humoral and cell-mediated immune responses against swine erysipelas |
As an accredited Swine Erysipelas Vaccine,Live Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Packaged as 10 doses per vial: lyophilized live vaccine in sterile, airtight glass vials with rubber stoppers and aluminum seals for veterinary use. |
| Container Loading (20′ FCL) | One 20′ FCL securely loaded with palletized, temperature-controlled Swine Erysipelas Vaccine, live veterinary API, for tablets, injections, capsules, powders, granules, premix, and solutions. |
| Shipping | Swine Erysipelas Vaccine, Live (Veterinary Grade API) ships as a temperature-controlled biological. Requires cold chain handling, typically at 2–8°C, to preserve viability. Packaged in insulated containers with validated coolants. For formulations including injections, tablets, powders, and premixes. Must avoid freezing, exposure to light, and delays. Ships with dry ice or gel packs depending on destination. |
| Storage | Store at 2–8°C (36–46°F) in a tightly sealed, original container. Protect from light, moisture, and freezing. Avoid temperature fluctuations; do not expose to direct sunlight. Handle under cold-chain conditions during transport and storage. Use before expiry. Keep out of reach of children and animals. |
| Shelf Life | Shelf life is typically 18–24 months when stored refrigerated at 2–8°C, protected from light and freeze-thaw cycles. |
Industrial conversion of Swine Erysipelas Vaccine, Live Veterinary Grade API into a sterile injectable suspension is the most mature downstream route for erysipelas control in growing and breeding pig herds. The live bacterial harvest is resuspended in a chilled phosphate-buffered stabiliser at pH 7.2–7.6, typically containing sucrose at 5–10% w/v and hydrolysed gelatin at 1–2% w/v to reduce cell wall and membrane damage during liquid handling. Formulated bulk is held at 2–8 °C for not more than 24 h before aseptic filling because published stability data for comparable live bacterial suspensions show a viable count decay of 0.1–0.3 log10 CFU/mL over 8 h at 20 °C. Target potency is commonly adjusted to 10⁸–10⁹ CFU per dose by blending concentrated harvest with the same stabiliser, and the final dose volume is usually 2 mL or 5 mL. Filling on production-scale lines uses peristaltic pumps with 0.8 mm bore silicone tubing; rotor speeds above 30 rpm have been associated with cell clumping and intermittent filter fouling at cell densities exceeding 10¹⁰ CFU/mL. The finished suspension is aseptically filled into Type I glass vials and sealed with bromobutyl rubber stoppers. No terminal heat, gas, or irradiation sterilisation can be applied without destroying the live antigen. Processing equipment is therefore sanitised by steam-in-place at 121 °C for 30 min, followed by aseptic assembly under ISO 14644-1 Grade A conditions. Sterility testing follows Ph. Eur. 2.6.1 or 9 CFR 113.26, and potency verification follows 9 CFR 113.67. Batch release includes identity by slide agglutination or PCR, viable count, pH, and absence of contaminating pathogens. The principal production failure mode is temperature excursion during the 24 h holding window, which can drop final titre below the approved minimum dose and require rejection of the entire batch.
Lyophilized powder for sterile injection is prepared where cold-chain infrastructure is not continuous or where extended shelf life is sought. The live API is formulated with a cryoprotective and lyoprotective matrix consisting of sucrose or trehalose at 5–15% w/v, mannitol at 2–4% w/v, and gelatin or sodium glutamate at 1–2% w/v. These stabilisers maintain colloidal glass structure and prevent intracellular ice damage during the freezing segment. Freezing on a production freeze dryer is controlled at a shelf ramp of 0.5–1.0 °C/min to -45 °C; uncontrolled fast freezing above 2 °C/min has been reported in comparable live bacterial vaccine batches to reduce post-lyophilization recovery by 0.5–1.0 log10 CFU/dose. Primary drying is conducted at shelf temperature -20 to -30 °C under a vacuum of 50–150 µbar for 24–48 h, with condenser capacity not less than 10 kg/24 h for 10 mL tubing vials. Residual moisture is controlled below 2.5% by Karl Fischer titration; batches above 3.0% residual moisture show accelerated viable count decay at 37 °C and are not released. Vials are stoppered under nitrogen or argon with headspace oxygen below 1% to limit oxidative membrane damage. The dried cake volume is usually 1–2 mL in a 10 mL vial, allowing reconstitution with 10 mL or 5 mL sterile diluent to obtain the final dose volume. Collapse temperature of the dried matrix is near -32 °C for sucrose-based formulations; shelf temperature excursions above this point during primary drying cause cake shrinkage, poor reconstitution, and viable count loss of 0.3–0.7 log10 CFU compared with intact plugs. The main production-scale failure modes are vial breakage when fill volume exceeds 5 mL in 10 mL vials, stopper moisture ingress during unloading, and irregular freezing at shelf edge positions. Reconstituted suspension must be used within 2 h when held at 2–8 °C; after this interval, potency decay may exceed the release specification for the live vaccine.
Oral powder and granule development for top-dress or feed application is constrained by gastric acid sensitivity and limited challenge-study data for live Erysipelothrix rhusiopathiae delivered by the enteral route. Published efficacy data for this specific API in oral dosage form is limited, and the route is not regarded as a direct substitute for parenteral administration unless a separate regulatory approval has been obtained. Where feasibility work is performed, low-shear wet granulation uses hydroxypropyl methylcellulose as binder at 4–8% w/w dry solid content, with granulation end point controlled at 10–14% moisture. Drying is conducted in a fluid-bed dryer at inlet air temperature 35–40 °C; higher moisture levels above 18% during drying have resulted in viability losses of 0.8–1.2 log10 CFU/g in pilot batches of comparable bacterial powders. Granules are screened through a 0.71 mm sieve to maintain dose uniformity below 5% coefficient of variation. The terminal powder or granule is packaged in laminated foil pouches with desiccant and stored at 2–8 °C; exposure to direct sunlight or ultraviolet light must be avoided because live bacterial cells are vulnerable to free radical damage. Microbial quality of the oral granule is assessed under Ph. Eur. 5.1.4 and the relevant product monograph. The main operational boundary is that oral vaccine delivery cannot be validated for this API without controlled enteric protection and evidence of mucosal immunity from challenge studies; without those data, powder and granule batches remain limited to experimental use.
Dry premix blending is an industrial route for uniform dispersion of live vaccine powder into a lactose monohydrate or dextrose carrier, but it is not automatically validated for this biological API and requires segregation from antibiotic and inactivated vaccine lines. Ribbon blenders of 0.5 m³ working volume are operated at 20 rpm or less for 10–15 min to avoid high shear heating; V-blenders and bin blenders may also be used when dust generation must be reduced. The carrier particle size is typically in the range of 80–120 µm D50 to improve flow and reduce segregation. Viable count loss during dry blending for comparable live bacterial powders is reported as 0.1–0.5 log10 CFU/g under controlled relative humidity below 30%. Production areas handling live antigen must be separated by physical barriers and operated under negative pressure with HEPA-filtered exhaust. Air cleanliness for powder handling follows ISO 14644-1 Class 8 or better, depending on the facility classification. The main constraints are dust carryover of live bacteria, container cleaning after batch completion, and the absence of terminal decontamination once the live API is dispersed in the premix. Published data for this exact swine erysipelas live vaccine API in feed premix dilution is limited; each facility must establish a process-specific recovery curve and a segregation validation report before commercial use.
Tablet and capsule dosage forms represent an exploratory extension of the API list rather than an established commercial route. Direct compression of live bacterial vaccine powder exposes cells to mechanical and thermal stress; for a 6 mm round flat-faced punch, a compression pressure of 50 MPa corresponds to approximately 1.4 kN compression force, and preliminary studies of comparable bacterial powders show viable count losses above 1 log10 CFU per tablet above this threshold. Tablet formulations intended for oral booster dosing therefore require low-compression rotary presses operating below 10 kN, external lubrication, and pre-compression at 2–4 kN to preserve cell integrity. Capsule filling with a low-speed dosator at 60 strokes/min or less generates lower shear than tableting but requires residual moisture below 3.0% and a desiccated environment below 25% relative humidity. The operational limitation is not only viable count loss during processing; the gastric residence environment and lack of validated enteric protection for live Erysipelothrix rhusiopathiae mean that oral tablets and capsules cannot be described as effective vaccine presentations without specific challenge-study documentation. Terminal products, if produced, must meet uniformity of dosage units under Ph. Eur. 2.9.5 or USP <905>, and residual moisture under the relevant pharmacopoeial method.
Solution and drench preparation from this live API is limited to reconstitution of lyophilized powder or dilution of a liquid concentrate with a chilled sterile diluent immediately before administration. Diluent temperature is held at 2–8 °C before mixing, and the final solution is buffered at pH 7.0–7.4 to avoid acid shock to the bacterial cells. Chlorinated water, hypochlorite residues, and metal ions at levels above 0.1 ppm are incompatible with live bacterial suspension stability and must be excluded. Mixing is conducted with a low-shear impeller at 50–100 rpm for not more than 5 min; high-speed homogenisation above 1,000 rpm has been associated with cell lysis in comparable bacterial suspensions. The finished solution is filled into amber glass or polypropylene drench containers with headspace oxygen below 1%. Once reconstituted, the solution must be used within 2 h at 2–8 °C or within 30 min at 25 °C, beyond which viable count decay may exceed the acceptance range. Drench administration equipment must be cleaned with sterile water and not with detergent residues, because surfactant carryover can disrupt the bacterial cell wall. Batch release tests include sterility if the solution is injected, or total aerobic microbial count and absence of specified pathogens if the solution is administered orally. The terminal product specification is governed by the approved route; for injectable solutions, Ph. Eur. 2.6.1 and 9 CFR 113.26 apply, and for oral solutions, Ph. Eur. 5.1.4 applies. The critical production risk is delay between reconstitution and administration, which cannot be corrected once viability loss has occurred.
| Process step | Reported viable count loss | Critical control variable | Reference method |
|---|---|---|---|
| Aseptic liquid filling | 0.1–0.3 log10 CFU/mL | Bulk hold time ≤ 24 h at 2–8 °C | Ph. Eur. 2.6.1, 9 CFR 113.26 |
| Lyophilization | 0.3–0.7 log10 CFU/dose | Shelf temperature -20 to -30 °C, residual moisture ≤ 2.5% | Karl Fischer, Ph. Eur. 2.5.12 |
| Wet granulation | 0.8–1.2 log10 CFU/g | Inlet air 35–40 °C, granule moisture ≤ 14% | Ph. Eur. 5.1.4 |
| Dry premix blending | 0.1–0.5 log10 CFU/g | Blender speed ≤ 20 rpm, relative humidity ≤ 30% | Total aerobic microbial count |
| Direct compression | 1.0–3.0 log10 CFU/unit | Compression pressure ≤ 50 MPa | Ph. Eur. 2.9.5, USP <905> |
| Compliance point | Specification or requirement | Reference standard |
|---|---|---|
| Sterility, injectable liquid | No growth after membrane filtration | Ph. Eur. 2.6.1, 9 CFR 113.26 |
| Potency, live erysipelas vaccine | Vaccination-challenge test in susceptible pigs or validated mouse model | 9 CFR 113.67 |
| Residual moisture, lyophilized powder | ≤ 2.5% | Ph. Eur. 2.5.12 |
| Uniformity of granules or tablets | Coefficient of variation ≤ 5.0% | Ph. Eur. 2.9.5, USP <905> |
| Microbial quality, oral powder or granule | Absence of specified pathogens and aerobic count within monograph limits | Ph. Eur. 5.1.4 |
| Identity | Confirmation by PCR or slide agglutination for Erysipelothrix rhusiopathiae | Master seed identity monograph |
Competitive Swine Erysipelas Vaccine,Live Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8615365186327
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
The product described as Swine Erysipelas Vaccine, Live, Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is a lyophilized live bacterial biological active substance derived from Erysipelothrix rhusiopathiae, intended for incorporation into veterinary medicinal products for active immunization of swine against erysipelas. No manufacturer-specific model designation is supplied in the product record; the compendial title and the batch-specific lot number therefore serve as primary identifiers, and any model code appearing on a certificate of analysis is internal to the producing facility. The material is manufactured from a defined master seed lot and working seed lot system under biological active substance GMP controls. Its functional distinction from inactivated erysipelas bacterins is the retention of viable, replication-competent bacterial cells. Consequently, every downstream operation is constrained by the requirement to preserve viability rather than merely chemical or antigenic integrity. The principal intended route is parenteral injection after reconstitution, but the listed dosage forms also create solid oral and premix formulation routes that require separate viability validation before routine use.
The release specification is dose-based rather than raw-powder-based. Viable count is the primary potency attribute and is commonly expressed as colony-forming units per pig dose; the minimum release titre is defined by the marketing authorization or manufacturing license rather than by a single compendial number. Identity is confirmed by slide agglutination with monospecific antiserum or by the manufacturer’s validated PCR method. Sterility is evaluated by membrane filtration or direct inoculation according to Ph. Eur. 2.6.1 or USP <71>. Residual moisture is determined by water determination according to Ph. Eur. 2.5.12 or USP <921>; lyophilized live bacterial vaccines typically carry a residual moisture acceptance criterion of ≤ 3.0% w/w, although the exact batch criterion is manufacturer-specific. Bacterial endotoxin is controlled according to Ph. Eur. 2.6.14 or USP <85>. Extraneous agent testing is conducted on the master seed lot and on production harvests; absence of mycoplasma is verified by culture according to Ph. Eur. 2.6.7, and freedom from specified viruses and bacteria is demonstrated before the harvest is accepted.
| Quality attribute | Reference method or standard | Function in live API control |
|---|---|---|
| Identity | Slide agglutination with monospecific antiserum; manufacturer’s validated PCR | Confirms Erysipelothrix rhusiopathiae serovar identity |
| Viable count | Serial dilution and plate count on selective agar | Standardizes dose and confirms replication competence |
| Sterility | Ph. Eur. 2.6.1 / USP <71> | Detects extraneous bacterial and fungal contamination |
| Residual moisture | Ph. Eur. 2.5.12 / USP <921> | Limits metabolic activity and improves storage stability |
| Bacterial endotoxin | Ph. Eur. 2.6.14 / USP <85> | Controls pyrogenic burden from gram-negative contaminants |
Production-scale lyophilizers used for this API exhibit batch-to-batch viability scatter when nucleation temperature, primary drying shelf temperature, and chamber pressure are not independently logged. The lyophilization cycle must keep the product temperature below the collapse temperature of the excipient matrix; for sucrose-based matrices, published freeze-drying literature places collapse temperature between -32 °C and -35 °C. The exact critical product temperature is measured by freeze-dry microscopy because a positive deviation of 2 °C above the collapse temperature can induce cake shrinkage, raise residual moisture, and reduce live count. At the end of drying, vials are backfilled with nitrogen to a defined chamber pressure and stoppered with low-moisture-vapor-transmission closures. Cold-chain storage is maintained at 2–8 °C; freeze-thaw cycles and sustained excursions above 8 °C accelerate metabolic deterioration and are reason for batch rejection. Headspace oxygen is commonly controlled to <1.0% v/v for nitrogen-flushed vials to limit oxidative damage to the dried bacterial biomass.
On a production line, potency drift is influenced not only by the freeze dryer but also by upstream fermentation and harvest. The bacterial biomass is produced in bioreactors under controlled pH, dissolved oxygen, and temperature; the optical density at harvest and the time from culture harvest to lyophilization influence final viable count. The survival factor across freeze-drying is expressed as log reduction between pre-lyophilization titre and post-lyophilization titre. Successful cycles carry a calculated overage linked to the minimum release titre. Scaling from pilot to commercial lyophilizers changes the ratio of shelf area to condenser capacity and can alter primary drying resistance; process transfer is therefore verified by comparative lyophilization runs rather than by geometric similarity alone. Published data for this specific configuration is limited, and the overage must be established by the marketing authorization holder.
Rotary tablet presses operating at 5–15 kN per station and high-shear mixer granulators with impeller tip speeds above 5 m/s generate mechanical stress and adiabatic heat that reduce the viability of unprotected lyophilized bacterial biomass. The inclusion of tablets and capsules in the dosage-form list does not imply that direct compression is a validated default; published data for this specific live erysipelas API in compressed solid dosage forms is limited. If a solid oral product is developed, the live biomass requires microencapsulation or lyophilized embedding in a cold-matrix carrier, and compression force must be justified by viable count retention rather than by tablet hardness alone. Ordinary dry blending for premix and granule formats is performed in low-shear tumble blenders or ribbon blenders with the live API added as the final component; high-shear intensifier bars are not used. Excipient pre-drying is required when ambient relative humidity exceeds 60%. The process must avoid continuous transfer lines with long residence times because metallic surfaces and frictional heating can create viable-count losses that are not visible by routine blend uniformity testing.
Capsule filling, when attempted, is limited to low-speed dosator-type machines with inlet air dew point controlled below 0 °C and relative humidity in the filling zone maintained at 20–30%. The filled capsules or granules must remain in cold-chain storage and cannot be subjected to enteric coating or hot-melt processes. For premix applications, the live API is not compatible with conventional feed pelleting temperatures or with steam conditioning, because thermal inactivation occurs rapidly in the presence of free moisture. Granules and premixes intended for oral delivery require dry, non-hygroscopic carriers and segregation from antibiotic-medicated feed lines. Residual moisture in the final premix above 12% w/w and carry-over of antimicrobial feed additives are both operational incompatibilities.
Relative to inactivated Erysipelothrix rhusiopathiae bacterins, this live API typically requires a lower antigen mass per dose and yields a qualitatively different immunological presentation. The inactivated API is compatible with oil adjuvants and is less sensitive to short-term ambient temperature excursion; the live API is not compatible with antimicrobial preservatives, terminal sterilizing filtration, or adjuvants that disrupt bacterial membranes. Manufacturing lines previously used for inactivated bacterins must be cleaned and validated for the absence of residual aldehydes, phenolic disinfectants, or mercury-based preservatives before live API processing. The live product also imposes a stricter cold-chain boundary: storage, transport, and in-process holding are maintained at 2–8 °C, while inactivated bacterins may tolerate defined ambient periods according to stability data.
Regulatory control of this API differs from that of a conventional chemical veterinary API. In the European Union, the material is subject to biological active substance requirements under EU GMP Annex 2 and to the specific provisions of the marketing authorization; in the United States, veterinary biologicals are regulated under 9 CFR Part 113 rather than as ordinary animal drugs under 21 CFR. The manufacturer’s master seed lot, working seed lot, and production serials are subject to safety, potency, and extraneous agent testing before release. These regulatory boundaries determine which process changes may be introduced without new validation. The field use of the material is expressed as a viability titre per animal dose rather than as milligrams per kilogram of body weight. This distinction has direct consequences for blending, scaling, and filling: batch calculations are based on target dose count and overfill rather than on weight/weight potency uniformity alone.
Reconstitution of the lyophilized API into an injectable solution is performed aseptically with the diluent specified in the marketing authorization. Terminal sterilizing filtration through 0.22 µm membranes is not applicable because the intact bacterial cells are retained by the filter; therefore the injectable product is produced by aseptic rehydration of the pre-sterilized API in an ISO 5 environment or a closed aseptic transfer system. The rehydrated suspension must not be mixed with antimicrobial diluents or with water from uncontrolled farm sources. In-use holding after reconstitution is controlled by the summary of product characteristics; published general guidance for live bacterial vaccines commonly limits refrigerated in-use holding to 4 h at 2–8 °C, but the batch-specific value must be followed. Needle-free injection equipment can be validated for viability preservation, but the shear generated by the device must be characterized because some needle-free injectors create pressure drops sufficient to reduce live bacterial counts.
Solution processing in a manufacturing setting requires stainless-steel or disposable aseptic mixing vessels; rotary lobe pumps and high-shear homogenizers are unsuitable for the rehydrated live suspension. Loading should be conducted with gentle magnetic stirring or low-speed impeller agitation below the energy threshold that causes bacterial cell damage. The production environment must maintain differential positive pressure and certified cleanroom classification. Sterile hold vessels and transfer lines are sterilized by steam-in-place or autoclave before use; residual condensate must be removed because free water initiates metabolic activity in the lyophilized biomass and reduces viable count during in-process holding.
The use profile differs from a conventional injectable chemical product because the active entity is a living organism. Administration in swine is typically intramuscular or subcutaneous according to the licensed schedule, and the dose must be delivered within the defined in-use period. Animals receiving immunosuppressive therapy or antibacterial treatment active against E. rhusiopathiae are unsuitable for vaccination during the treatment window. This live API is not interchangeable with inactivated erysipelas vaccines on a volume-to-volume basis; the viable count, the adjuvanted or non-adjuvanted formulation, and the route of administration all determine the final immunological performance. Published data for this specific configuration is limited, but the general behavior of live bacterial vaccines under production and field handling is documented in veterinary biological product monographs and manufacturer technical dossiers.
